Drug Profile
NI 007
Alternative Names: Anti-SARS-CoV-2 neutralising antibody; NI007Latest Information Update: 08 Sep 2020
Price :
$50
*
At a glance
- Originator ethris; Neurimmune Therapeutics
- Developer Ethris; Neurimmune Therapeutics
- Class Antivirals; Monoclonal antibodies; RNA
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 08 Sep 2020 Preclinical trials in COVID-2019 infections in Switzerland (Inhalation) before September 2020 (Neurimmune Therapeutics pipeline, September 2020)
- 01 Apr 2020 Neurimmune and Ethris agree to co-develop NI 007 for COVID-2019 infections
- 01 Apr 2020 Early research in COVID-2019 infections in Switzerland (Inhalation)